Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,119 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse.
Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N, Cross M, Maier J, Niederwieser D, Wickenhauser C. Lange T, et al. Among authors: maier j. Haematologica. 2013 May;98(5):722-8. doi: 10.3324/haematol.2012.076901. Epub 2013 Jan 8. Haematologica. 2013. PMID: 23300178 Free PMC article.
The quantitative level of T315I mutated BCR-ABL predicts for major molecular response to second-line nilotinib or dasatinib treatment in patients with chronic myeloid leukemia.
Lange T, Ernst T, Gruber FX, Maier J, Cross M, Müller MC, Niederwieser D, Hochhaus A, Pfirrmann M. Lange T, et al. Among authors: maier j. Haematologica. 2013 May;98(5):714-7. doi: 10.3324/haematol.2012.068890. Epub 2012 Oct 12. Haematologica. 2013. PMID: 23065514 Free PMC article.
A co-operative evaluation of different methods of detecting BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on second-line dasatinib or nilotinib therapy after failure of imatinib.
Ernst T, Gruber FX, Pelz-Ackermann O, Maier J, Pfirrmann M, Müller MC, Mikkola I, Porkka K, Niederwieser D, Hochhaus A, Lange T. Ernst T, et al. Among authors: maier j. Haematologica. 2009 Sep;94(9):1227-35. doi: 10.3324/haematol.2009.006981. Epub 2009 Jul 16. Haematologica. 2009. PMID: 19608684 Free PMC article. Clinical Trial.
Optimized Digital Droplet PCR for BCR-ABL.
Maier J, Lange T, Cross M, Wildenberger K, Niederwieser D, Franke GN. Maier J, et al. J Mol Diagn. 2019 Jan;21(1):27-37. doi: 10.1016/j.jmoldx.2018.08.012. Epub 2018 Oct 19. J Mol Diagn. 2019. PMID: 30347270 Free article.
Circulating cKIT and PDGFRA DNA indicates disease activity in Gastrointestinal Stromal Tumor (GIST).
Jilg S, Rassner M, Maier J, Waldeck S, Kehl V, Follo M, Philipp U, Sauter A, Specht K, Mitschke J, Lange T, Bauer S, Jost PJ, Peschel C, Duyster J, Gaiser T, Hohenberger P, von Bubnoff N. Jilg S, et al. Among authors: maier j. Int J Cancer. 2019 Oct 15;145(8):2292-2303. doi: 10.1002/ijc.32282. Epub 2019 Apr 29. Int J Cancer. 2019. PMID: 30882891 Clinical Trial.
Prevalence and dynamics of bcr-abl kinase domain mutations during imatinib treatment differ in patients with newly diagnosed and recurrent bcr-abl positive acute lymphoblastic leukemia.
Pfeifer H, Lange T, Wystub S, Wassmann B, Maier J, Binckebanck A, Giagounidis A, Stelljes M, Schmalzing M, Dührsen U, Wunderle L, Serve H, Brück P, Schmidt A, Hoelzer D, Ottmann OG. Pfeifer H, et al. Among authors: maier j. Leukemia. 2012 Jul;26(7):1475-81. doi: 10.1038/leu.2012.5. Epub 2012 Jan 9. Leukemia. 2012. PMID: 22230800
Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells.
Bolton-Gillespie E, Schemionek M, Klein HU, Flis S, Hoser G, Lange T, Nieborowska-Skorska M, Maier J, Kerstiens L, Koptyra M, Müller MC, Modi H, Stoklosa T, Seferynska I, Bhatia R, Holyoake TL, Koschmieder S, Skorski T. Bolton-Gillespie E, et al. Among authors: maier j. Blood. 2013 May 16;121(20):4175-83. doi: 10.1182/blood-2012-11-466938. Epub 2013 Mar 29. Blood. 2013. PMID: 23543457 Free PMC article.
1,119 results